- Home
- MFIN vs FENC Comparison
MFIN vs FENC Comparison
Compare MFIN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$7.62
Company Overview
Basic Information| Metric | MFIN | FENC |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 258.5M |
| IPO Year | 1996 | 2001 |
Fundamental Metrics
Financial Performance| Metric | MFIN | FENC |
|---|---|---|
| Price | $10.51 | $7.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $13.50 |
| AVG Volume (30 Days) | 44.0K | ★ 219.0K |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | ★ 1.06 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $338,783,000.00 | $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.83 | $75.22 |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | ★ 15.53 | N/A |
| 52 Week Low | $7.71 | $4.68 |
| 52 Week High | $10.98 | $9.92 |
Technical Indicators
Market Signals| Indicator | MFIN | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 60.67 | 42.20 |
| Support Level | $9.96 | $7.35 |
| Resistance Level | $10.39 | $7.74 |
| Average True Range (ATR) | 0.31 | 0.36 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 87.87 | 20.00 |
Price Performance
Historical Comparison MFIN
FENC
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.